Semaglutide for Chronic Pain
Weight loss from GLP-1 treatment significantly reduces mechanical stress on joints and decreases systemic inflammation that contributes to chronic pain. Semaglutide (Wegovy/Ozempic) is a GLP-1 receptor agonist shown to produce 15% average body weight loss in clinical trials.
How Semaglutide Helps with Chronic Pain
Semaglutide mimics the GLP-1 hormone to reduce appetite and slow stomach emptying, leading to significant weight loss. For patients with chronic pain, this weight loss translates to meaningful improvements in condition-specific outcomes.
Weight loss from GLP-1 treatment significantly reduces mechanical stress on joints and decreases systemic inflammation that contributes to chronic pain. The STEP clinical trial program demonstrated that semaglutide 2.4mg weekly produces an average weight loss of 15% of body weight over 68 weeks, with additional benefits for metabolic health markers.
Clinical Evidence for Chronic Pain
Chronic Pain affects over 50 million adults in the United States. Research shows that GLP-1 medications like semaglutide address both the weight component and the underlying metabolic dysfunction associated with chronic pain. Patients with this condition often see compounding benefits from weight loss, including improved energy, mobility, and overall quality of life.
Semaglutide Dosing for Chronic Pain
Semaglutide is taken as a once-weekly subcutaneous injection. The standard titration starts at 0.25mg and gradually increases to the maintenance dose of 2.4mg over 16-20 weeks. Dosing is the same regardless of the indication — your provider will monitor your response and adjust timing as needed.
Cost of Semaglutide for Chronic Pain
Compounded semaglutide costs $149-399/month through telehealth providers. Brand-name Wegovy costs $1,300+/month without insurance. Many patients with chronic pain have associated comorbidities that improve insurance coverage chances.